Hypoalbuminemia in Guillain-Barré syndrome

Abstract

Shalman and colleagues reported a case of Guillain-Barré syndrome (GBS) whose clinical response to a second course of intravenous immunoglobulin (IVIG) treatments was associated with the albumin level in serum [1]. They concluded that serum albumin levels may be viewed a biomarker as part of the decision algorithm when a second course of IVIG treatment is considered [1]. This case report is interesting, and its finding is consistent with a former clinical trial suggesting that serum albumin could be a potential biomarker to monitor the treatment responses to IVIg among patients with GBS [2].